• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down 2.84% Nasdaq Down 2.94%

    More On GLENMARK.NS

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials

    Glenmark Pharmaceuticals Ltd. (GLENMARK.NS)

    -NSE
    1,101.30 Down 23.20(2.06%) 11:56PM EDT
    Add to Portfolio
    Prev Close:1,124.50
    Open:1,125.65
    Bid:1,101.30
    Ask:1,101.35
    1y Target Est:N/A
    Beta:N/A
    Next Earnings Date:N/A
    Day's Range:1,098.00 - 1,133.60
    52wk Range:676.00 - 1,262.90
    Volume:148,311
    Avg Vol (3m):1,397,870
    Market Cap:304.36B
    P/E (ttm):62.36
    EPS (ttm):17.66
    Div & Yield:N/A (N/A)
    Quotes delayed, except where indicated otherwise. Currency in INR.

    Headlines

    • No Headlines available for GLENMARK.NS at this time.

    Key Statistics

    Forward P/E (1 yr):N/A
    P/S (ttm):4.60
    Ex-Dividend Date:N/A

    Analysts

    Annual EPS Est () :N/A
    Quarterly EPS Est () :N/A
    Mean Recommendation*:N/A
    PEG Ratio (5 yr expected):N/A

    * (Strong Buy) 1.0 - 5.0 (Sell)

    Analyst Opinion | Estimates

    Business Summary

    Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products. The company’s products include Crofelemer, an anti diarrheal drug for symptomatic relief of non-infectious diarrhoe... View More
    Your browser doesn't support canvas
    SETTINGS
    Scrolling
    Speed
    Display
    Price
    Submit Feedback